e-Article
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.
Document Type
Article
Author
Tucker, Laura; Allen, Alexander; Chandler, David; Ciurtin, Coziana; Dick, Andrew; Foulkes, Amy; Gullick, Nicola; Helliwell, Philip; Jadon, Deepak; Jones, Gareth; Kyle, Stuart; Madhok, Vishnu; McHugh, Neil; Parkinson, Andrew; Raine, Tim; Siebert, Stefan; Smith, Catherine; Tillett, William; Coates, Laura C
Source
Subject
*DRUG therapy for arthritis
*PSORIATIC arthritis
*THERAPEUTICS
*LIFESTYLES
*ANTIRHEUMATIC agents
*TREATMENT effectiveness
*DRUG prescribing
*DECISION making
*MEDICAL prescriptions
*PHYSICIAN practice patterns
*SYMPTOMS
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1462-0324
Abstract
The article discusses the 2022 British Society for Rheumatology (BSR) guidelines for the use of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the treatment of patients with psoriatic arthritis (PsA). Topics explored include the clinical characteristics and prevalence of PsA, results of randomized clinical trials of synthetic DMARDs, and the DMARDs prescribing and treatment strategies.